A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Rapport Therapeutics, Inc. Common Stock RAPP
Mixed (early) broader-coverage candidate · Rapport Therapeutics, Inc.
On FrontierLab's discovery record since 2026-09-22 (2 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-09-23), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | — |
|---|---|
| Gross margin | 100% |
| Gross profits / assets | 0.04 |
| Rule of 40 | — |
| Net margin | -767.6% |
| Cash runway (months) | 54.1 |
| PEG | — |
| Price / sales | 99.2 |
Quality checklist
- ✗ Capital efficiency
- ✓ Gross margin — 100% (pass ≥ 60%)
- ✓ Share dilution — 33.9%
Fundamentals — snapshot as of 2026-09-23
| Stage | Early |
|---|---|
| Share issuance (YoY) | 33.9% · heavy issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | — |
| EPS (trailing) | $-3.04 |
| Burn multiple | 4.8 |
| Gross-margin trend (pts) | — |
| Cash / assets | 0.95 |
| Net debt / EBITDA | — |
| Statements as of | Q2 FY2026 · filed 2026-08-05 |
Momentum context — a snapshot from 2026-09-23, not current
| Price at surface | $41.47 (as of 2026-09-23) |
|---|---|
| 52-week range | $23.75 – $52.93 |
| % off 52-wk high | -21.7% |
| RSI (14) | 39 |
| Relative volume | 2.3× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-09-23 (end-of-day). How grades are computed →